Stromedix Sets Sight on Trial for Pulmonary Fibrosis

Cambridge, MA-based Stromedix is planning to begin a mid-stage trial of its lead drug in patients with a chronic lung disease called idiopathic pulmonary fibrosis before the end of June, CEO Michael Gilman said.
Xconomy